WAY-260022

CAS No. 850692-43-2

WAY-260022( —— )

Catalog No. M33964 CAS No. 850692-43-2

WAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    WAY-260022
  • Note
    Research use only, not for human use.
  • Brief Description
    WAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.
  • Description
    WAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    Dopamine Receptor | Serotonin Transporter | Norepinephrine
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    850692-43-2
  • Formula Weight
    400.48
  • Molecular Formula
    C21H31F3N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](CN1C[C@H](C)N[C@H](C)C1)(C2(O)CCCCC2)C3=CC(OC(F)(F)F)=CC=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Bromopride

    Bromopride is a dopamine antagonist with prokinetic properties closely related to metoclopramide, and is widely used as an antiemetic.

  • Cariprazine HCl

    Cariprazine HCl is an antipsychotic drug is a D3 and D2?receptor partial agonist((Ki of 0.085 nM and 0.49 nM respectively).

  • Syrosingopine

    Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor.